gw501516 product description:
1. gw-501516, better known as cardarine, is a unique medication officially classified as a ppar receptor agonist (ppar-ra). research for this medication began in 1992 in a conjoined effort between glaxosmithkline (gsk) and ligand pharmaceuticals.
2. research into this product was set forth in an effort to provide treatment for various cardiovascular diseases, as well as diabetes, obesity and other conditions.
3. it was soon discovered that the ppar-ra was highly effective at enhancing endurance, but it was also shown to carry a high potential cost. it was discovered that cardarine increased the chances of cancer significantly, and as a result, gsk dropped all further research.
4. however, the studies that produced cancerous results used doses of cardarine that were 500 to even 1000 times the amount that a human being would take. if cancer is a risk with standard dosing is unknown.
5. cardarine (gw-501516) binds to the ppar receptor, specifically a group of nuclear receptors (sensors that detect thyroid and steroidal hormones in the body) that initiates the pgc-1a enzyme.
6. this action leads to gene expression, specifically genes that revolve around energy expenditure.
studies involving gw-501516 have shown to increase the metabolism of fatty acids in rats.
7. it was also shown in the same studies to reduce the odds of obesity despite poor eating habits as well as prevent type-2 diabetes.
8. cardarine was also shown to increase hdl (good cholesterol) and decrease ldl (bad cholesterol) in a study using monkeys. the effects seemed to hold true with or without exercise